Objective: To determine the di erence in serum Elabela level in hypertensive patients with and without nephropathy compared to the healthy control group. Study Desing: Cross-sectional descriptive study. Place and Duration of Study: F1rat University Medical School, Elazig, Turkey between December 2018 and November 2020. Methodology: The cross-sectional descriptive study consisted of 37 patients with hypertensive nephropathy (group 3), 50 hypertensive patients without nephropathy (group 2), and 50 healthy controls (group H1y)p. ertensive nephropathy was de ned as serum creatinine e1.8 mg / dl or GFR <40 ml / minute. Biochemical parameters (Glucose, AST, ALT, urea, creatinine, lipid levels, hemogram, calcium, phosphorus, parathormone) and the levels of serum Elabela were evaluated and compared. Results: There was no signi cant di erence in age (0.270) and gender (0.951) between groupsT.he median Elabela levels of the three groups were 40.3 ng/mL (22.5-54.6), 5.1 ng/mL (3.7-8.3), 9.2 ng/mL (6.1-23.1), respectively with a signi cant di erence (p<0.001). Conclusion: The plasma levels of Elabela were lower in the case of hypertension, independent of nephropathyH.owever, this decrease is not speci c for nephropathy and may be due to other accompanying chronic diseases.